Compare Immunovant Inc. Common Stock (IMVT) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Samsara Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B), while Samsara Inc trades at $41.53 (market cap $24.14B). The key difference: Samsara Inc is far larger — about 3.9× Immunovant Inc. Common Stock's market cap, and Samsara Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Samsara Inc for 19 Days on average.
| IMVT | IOT | |
|---|---|---|
Market Cap | $6.25B | $24.14B |
Volume | 1,755,411 | 5,372,580 |
Sector | Health | Technology |
52-Week High | $44.96 | $45.22 |
52-Week Low | $17.03 | $24.25 |
Typical Hold Time | 1 Days | 19 Days |
Enterprise Value | $5.35B | $23.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Samsara Inc. (IOT) trades at $41.61, up 2.72% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.20 exceeding the $0.16 forecast. Revenue growth is robust, projected to rise from $1.25 billion in 2025 to $1.8 billion in 2026, while the company transitions to profitability with a net margin of 4.9% in 2026. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.
The investment outlook is positive, driven by earnings beats, revenue acceleration, and a consensus price target of $51.15 implying 23% upside. However, high valuation multiples (P/E of 274.8, P/S of 13.01) pose risks if growth slows. Cash flow pressures in 2026 and insider selling are additional concerns. The stock's momentum depends on sustaining its growth trajectory amid competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
